3,7-dihydroxy-12-oxocholanoic acid has been researched along with Diabetes Mellitus, Type 1 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I | 1 |
1 other study(ies) available for 3,7-dihydroxy-12-oxocholanoic acid and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Chenodeoxycholic Acid; Cholic Acids; Chromatography, High Pressure Liquid; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Food-Drug Interactions; Gliclazide; Hypoglycemic Agents; Injections, Intravenous; Male; Probiotics; Random Allocation; Rats; Rats, Wistar | 2012 |